Rubicon Research Ltd

Rubicon Research Ltd is rated Strong Buy by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 July 2026, providing investors with the most up-to-date view of its performance and prospects.

Surging to an intraday peak of Rs 1525.25 on 14 Jul 2026, Rubicon Research Ltd has reached a fresh 52-week and all-time high, propelled by a confluence of bullish technical indicators and sustained price momentum that outpaces its sector and broader market trends.

Rubicon Research Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by touching an all-time high stock price of Rs.1500 on 14 July 2026. This achievement reflects the company’s robust performance and sustained upward momentum in the market.

Rubicon Research Ltd has demonstrated a marked shift in technical momentum, with key indicators signalling a transition from mildly bullish to a more confident bullish stance. Supported by strong price action and robust technical signals, the pharmaceutical and biotechnology small-cap is showing promising signs of sustained upward movement, outperforming broader market benchmarks.

With a sustained six-day rally culminating in a fresh 52-week high of Rs 1481.6 on 13 Jul 2026, Rubicon Research Ltd has demonstrated remarkable price momentum, outpacing its sector and signalling robust technical alignment across multiple timeframes.

Rubicon Research Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, achieved a significant milestone on 13 Jul 2026 by reaching its all-time high stock price of Rs.1481.6. This landmark event reflects the company’s robust performance and sustained growth trajectory within the small-cap segment.

Rubicon Research Ltd is rated Strong Buy by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 05 July 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Rubicon Research Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, prompting an upgrade to a Strong Buy rating with a robust Mojo Score of 82.0 as of 1 June 2026. This article analyses the recent technical indicator changes, price momentum, and comparative returns that underpin this bullish outlook.

Rubicon Research Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, achieved a significant milestone on 24 June 2026 by reaching its all-time high stock price of Rs.1420.6. This landmark event reflects the company’s robust performance and sustained upward momentum in the market.

Rubicon Research Ltd is rated Strong Buy by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 24 June 2026, providing investors with the latest insights into the company’s performance and outlook.

With a decisive break above Rs 1420.6 on 24 Jun 2026, Rubicon Research Ltd has reached a fresh 52-week and all-time high, propelled by a confluence of bullish technical indicators and sustained price momentum over recent sessions.

Rubicon Research Ltd has demonstrated a significant shift in its technical momentum, upgrading from a mildly bullish to a bullish stance, supported by robust signals from key indicators such as MACD, Bollinger Bands, and Dow Theory. With a current market price of ₹1,387.55 and a strong Mojo Score of 90.0, the pharmaceutical and biotechnology company is now rated a Strong Buy, reflecting growing investor confidence amid impressive price returns and technical strength.

Rubicon Research Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently exhibited a notable shift in its technical parameters, reflecting a nuanced price momentum. While the company’s stock price surged to ₹1,377.45 on 23 Jun 2026, up 1.28% from the previous close of ₹1,360.00, technical indicators reveal a blend of bullish and bearish signals that investors should carefully analyse.

With a decisive surge to Rs 1413.75 on 22 Jun 2026, Rubicon Research Ltd has reached a fresh 52-week and all-time high, propelled by a confluence of bullish technical indicators and sustained price momentum.

Rubicon Research Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, achieved a significant milestone on 22 June 2026 as its stock price reached an all-time high, closing at Rs 1,407.85. This landmark event reflects the company’s robust performance and sustained upward momentum in the market.

Rubicon Research Ltd has demonstrated a significant shift in price momentum, supported by a series of bullish technical indicators and an upgraded rating to Strong Buy. The pharmaceutical and biotechnology company’s stock price has surged to ₹1,355, nearing its 52-week high of ₹1,399.45, reflecting robust investor confidence and a positive outlook in a challenging market environment.

With a decisive break above Rs 1399.45 on 16 Jun 2026, Rubicon Research Ltd has reached a new 52-week and all-time high, propelled by a confluence of bullish technical indicators and sustained price momentum.